Investor Relations

Latest News

View All News

FibroBiologics Files 2023 Form 10-K Annual Report

Read Press Release

FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum

Read Press Release
employees discussing with whiteboard

Upcoming Event

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024

Company Information

FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

View Executive Team
View Board of Directors

Latest Financial Results

FY 2023

Fiscal Year Ended Dec 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

IR Contacts

Company

FibroBiologics Inc.
455 E. Medical Center Blvd.
Suite 300
Houston, TX 77598
T: 281-671-5150
info@fibrobiologics.com

Investor Relations

Russo Partners
Nic Johnson or Harrison Seidner, Ph.D.
T: 212-845-4242
fibrobiologicsIR@russopr.com

Transfer Agent

VStock Transfer LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436